Refining the efficacy of systemic administration of bioactive molecules for Parkinson's Disease - RePark
Project summary
Parkinson’s Disease (PD) is a neurodegenerative disease primarily linked to ageing affecting the psychomotor functions. An impairment in the activity of dopaminergic neurons (aggregation and intracellular accumulation of alfa-synuclein), is at the basis of this functional loss. Current therapies do not revert the PD progression but stand on the relief of the symptoms. Importantly, the efficacy of new therapeutic approaches is hampered by the lack of in vitro models that mimic the PD’s hallmarks. Moreover, the effectiveness of therapeutic approaches is hampered by the low ability of the drugs to cross the blood-brain barrier (BBB). RePark will develop an in vitro PD model that combines a mimic of the BBB, the brain’s extracellular matrix (ECM) and brain cells. With this system it will be possible to overcome the disadvantages of using animal models and to recapitulate in vitro the cellular characteristics of PD, as well as to assess the delivery and efficacy of new therapeutic drugs.Project Details
Call
Call 2021
Call Topic
New strategies for advanced material-based technologies for health applications
Project start
01.10.2022
Project end
30.09.2025
Total project costs
650.506 €
Total project funding
646.503 €
TRL
1 - 4
Coordinator
Dr. Ricardo Pires
rpires@i3bs.uminho.pt
University of Minho, LARGO DO PACO, 4704 553 BRAGA, Portugal
Partners and Funders Details
Consortium Partner | Country | Funder | |
---|---|---|---|
University of Antwerp https://www.uantwerpen.be/en/ |
University | Belgium | BE-FWO |
University of Minho |
University | Portugal | PT-FCT |
Tel Aviv University |
University | Israel | IL-MOST IL |